abt-384
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00968422)
Timeline
Indications
Mechanism of action
- 11-beta-hydroxysteroid dehydrogenaseINHIBITOR
11-beta-hydroxysteroid dehydrogenase inhibitor
11-beta-hydroxysteroid dehydrogenase 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(C(=O)NC1C2CC3CC1CC(C(N)=O)(C3)C2)N1CCN(c2ccc(C(F)(F)F)cn2)CC1- Mol. weight
- 493.57 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297256 ↗
Also known as
- abt-384
- abt-384
- abt-384
- abt-384
- n-(5-(aminocarbonyl)tricyclo(3.3.1.13,7)dec-2-yl)-alpha,alpha-dimethyl-4-(5-(trifluoromethyl)-2-pyridinyl)-1-piperazineacetamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01137526 | Phase 2 | May 1, 2010 | AbbVie |
| NCT01009216 | Phase 1 | Oct 1, 2009 | Abbott |
| NCT00968422 | Phase 1 | Aug 1, 2009 | Abbott |
Showing 3 of 3 trials
Page 1 / 1